Temozolomide and radiotherapy in newly diagnosed glioblastoma patients: O 6-methylguanine-DNA methyltransferase (MGMT) promotor methylation status and Ki-67 as biomarkers for survival and response to treatment

Chinese-German Journal of Clinical Oncology

Volumn 11, Issue 3, 2012, Pages 168-176

  Karim, K Abdel ^a   El Mahdy, M M ^a   Wahab, M M Abdel ^a   Ei Arab, L R Ezz ^a   El Shehaby, A ^a   Raouf, S Abdel ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Glioblastoma; Ki 67; O 6 methylguanine DNA methyltransferase (MGMT); Temozolomide

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER PATIENT; CANCER PROGNOSIS; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DNA METHYLATION; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LYMPHOCYTOPENIA; MALE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 84860813902     PISSN: 16101979     EISSN: 16139089     Source Type: Journal    
DOI: 10.1007/s10330-011-0928-y     Document Type: Article

References (50)

1. Taylor RE. Defining the standard of care for high- grade glioma - NICE deal for patients. Clin Oncol, 2008, 1: 97-98.
2. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastoma: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol, 2005, 23: 2411-2422. (Pubitemid 46218735)
3. Lefranc F, Sadeghi N, Camby I, et al. Present and potential future issues in glioblastoma treatment. Expert Rev Anticancer Ther, 2006, 6: 719-732. (Pubitemid 44192888)
4. Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol, 2002, 64: 259-273. (Pubitemid 35254019)
5. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet, 2002, 359: 1011-1018. (Pubitemid 34286538)
6. van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumours: The European Organization for Research and Treatment of Cancer, brain tumor group study 26971. J Clin Oncol, 2003, 21: 2525-2528. (Pubitemid 46606334)
7. Stupp R, Mason WP, Van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblasoma. N Engl J Med, 2005, 352: 987-996. (Pubitemid 40349501)
8. Clark AS, Deans B, Stevens MF, et al. Antitumor imidazotetrazines. 32.1 Synthesis of novel imidazotetrazinones and related bicyclic hetrocycles to probe the mode of action of the antitumor drug temozolomide. J Med Chem, 1995, 38: 1493-1504.
9. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol, 2002, 20: 2388-2399. (Pubitemid 34441669)
10. Pegg AE, Dolan ME, Moschel RC. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol, 1995, 51: 167-223.
11. Kaina B, Christmann M. DNA repair in resistance to alkylating anticancer drugs. Int J Clin Pharmacol Ther, 2002, 40: 354-367. (Pubitemid 34846106)
12. Pagani E, Pepponi R, Fuggetta MP, et al. DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system. J Chemother, 2003, 15: 173-183. (Pubitemid 36609755)
13. Pepponi R, Marra G, Fuggetta MP, et al. The effect of O6-alkylguanine- DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis (2-chloroethyl) 1-nitrosourea, and cisplatin. J Pharmacol Exp Ther, 2003, 304: 661-668. (Pubitemid 36152342)
14. Roos W, Baumgartner M, Kaina B. Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. Oncogene, 2004, 23: 359-367. (Pubitemid 38174989)
15. Barvaux VA, Ranson M, Brown R, et al. Dual repair modulation reverses Temozolomide resistance in vitro. Mol Cancer Ther, 2004, 3: 123-127. (Pubitemid 39193686)
16. Silber JR, Bobola MS, Ghatan S, et al. O6-Methylguanine-DNA methylltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res, 1998, 58: 1068-1073. (Pubitemid 28182481)
17. Esteller M, Garcia-Foncillas J, Andion E, et al. Incativation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med, 2000, 343: 1350-1354.
18. Kayaselçuk F, Zorludemir S, Gümürdühü D, et al. PCNA and Ki-67 in central nervous system tumours: Correlation with the histological type and grade. J Neuroonocol, 2002, 57: 115-121. (Pubitemid 34692618)
19. Castilla EA, Prayson RA, Kanner AA, et al. Cycloozygenase-2 in oligodendroglial neoplasms. Cancer, 2003, 98: 1465-1472.
20. Tortosa A, Vinolas N, Villá S, et al. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic glioma. Cancer, 2003, 97: 1063-1071. (Pubitemid 36173159)
21. Louis DN, Ohgaki H, Wiestler OD, et al, editors. WHO classification of tumors of the central nervous system. Lyon: IARC press, 2007.
22. Cao VT, Jung TY, Jung S, et al. The correlation and prognostic significance of MGMT prometer methylation and MGMT protein in Glioblastomas. Neurosurgery, 2009, 65: 866-875.
23. Yoon SO, Kim YA, Jeon YK, et al. Diffuse large B-cell lymphoma shows distinct methylation profiles of the tumor suppressor genes among the Non-Hodgkin's lymphomas. Korean J Pathol, 2008, 42: 16-20.
24. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res, 2004, 10: 1871-1874. (Pubitemid 38375541)
25. Chinot OL, Barrie M, Fuentes S, et al. Correlation between O6-methyl guanine-DNA-methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol, 2007, 25: 1470-1475. (Pubitemid 46733073)
26. Blough MD, Zlatescu MC, Cairncross JG. O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells. Cancer Res, 2007, 67: 580-584. (Pubitemid 46192195)
27. Lavon I, Fuchs D, Zrihan D, et al. Novel mechanism whereby nuclear factor κB mediates DNA damage repair through regulation of O6-methylguanine-DNA- methyltransferase. Cancer Res, 2007, 67: 8952-8959. (Pubitemid 47437473)
28. Blanc JL, Wager M, Guilhot J, et al. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol, 2004, 68: 275-283. (Pubitemid 38878263)
29. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 2005, 352: 997-1003. (Pubitemid 40349502)
30. Glas M, Happold C, Rieger J, et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol, 2009; 27, 8: 1257-1261.
31. Komine C, Watanabe T, katayama Y, et al. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltranseferase is an independent predictor of shortened progression free survival in patient with low-grade diffuse astrocytomas. Brain Pathol, 2003, 13: 176-184. (Pubitemid 36460818)
32. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 2009, 10: 459-466.
33. Herrlinger U, Rieger J, Kock D, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol, 2006, 24: 4412-4417. (Pubitemid 46630979)
34. Preusser M, Charles Janzer R, Felsberg J, et al. Anti-O6-methylguanine- methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol, 2008, 18: 520-532.
35. Grasbon-Frodl EM, Kreth FW, Ruiter M, et al. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer, 2007, 121: 2458-2464. (Pubitemid 350022415)
36. Maxwell JA, Johnson SP, Quinn JA, et al. Quantitative analysis of O6- alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther, 2006, 5: 2531-2539. (Pubitemid 44650917)
37. Jeuken JW, Cornelissen SJ, Vriezen M, et al. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest, 2007, 87: 1055-1065. (Pubitemid 47429190)
38. Rodriguez FJ, Thibodeau SN, Jenkins RB, et al. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol, 2007, 16: 59-65.
39. Nakasu S, Fukami T, Baba K, et al. Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol, 2004, 70: 333-340. (Pubitemid 40057961)
40. Brell M, Tortosa A, Verger E, et al. Prognostic significance of O6- methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res, 2005, 11: 5167-5174. (Pubitemid 41003702)
41. Criniére E, Kaloshi G, Laigle-Donadey F, et al. MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol, 2007, 83: 173-179. (Pubitemid 46784990)
42. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res, 2004, 10: 4933-4938. (Pubitemid 39099766)
43. Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer, 2006, 95: 1155-1160. (Pubitemid 44658477)
44. Mc Cabe MT, Low JA, Daignault S, et al. Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res, 2006, 66: 385-392. (Pubitemid 43166046)
45. Stupp R, Hegi ME. Methylguanine methyltransferase testing in glioblastoma: when and how? J Clin Oncol, 2007, 25: 1459-1460. (Pubitemid 46733069)
46. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst, 1993, 85: 704-710. (Pubitemid 23133591)
47. Ammirati M, Vick N, Liao YL, et al. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosugery, 1987, 21: 201-206. (Pubitemid 17131119)
48. Huang L, Jiang T, Yuan F, et al. Correlation of chromosomes 1P and 19q status and expressions of O6-methylguanine-DNA methyltransferase (MGMT)-p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study. Neuropathol Appl Neurobiol, 2009, 35: 367-379.
49. Eneström S, Vavruch L, Franlund B, et al. Ki-67 antigen expression as a prognostic factor in primary and recurrent astrocytomas. Neurochirurgie, 1998, 44: 25-30. (Pubitemid 28157370)
50. Reavey-Cantwell JF, Haroun RI, Zahurak M, et al. The prognostic value of tumor markers in patients with glioblastoma multiforme: Analysis of 32 patients and review of the literature. J Neurooncol, 2001, 55: 195-204. (Pubitemid 34134044)